.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Citi
Merck
Teva
Fuji
Chubb
Cantor Fitzgerald
Moodys
Cipla
QuintilesIMS

Generated: September 19, 2017

DrugPatentWatch Database Preview

ASACOL HD Drug Profile

« Back to Dashboard

What is the patent landscape for Asacol Hd, and what generic Asacol Hd alternatives are available?

Asacol Hd is a drug marketed by Apil and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventeen patent family members in seventeen countries.

The generic ingredient in ASACOL HD is mesalamine. There are twenty-seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

Summary for Tradename: ASACOL HD

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list112
Clinical Trials: see list28
Patent Applications: see list6,007
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ASACOL HD at DailyMed

Pharmacology for Tradename: ASACOL HD

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil
ASACOL HD
mesalamine
TABLET, DELAYED RELEASE;ORAL021830-001May 29, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Apil
ASACOL HD
mesalamine
TABLET, DELAYED RELEASE;ORAL021830-001May 29, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Apil
ASACOL HD
mesalamine
TABLET, DELAYED RELEASE;ORAL021830-001May 29, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ASACOL HD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil
ASACOL HD
mesalamine
TABLET, DELAYED RELEASE;ORAL021830-001May 29, 2008► Subscribe► Subscribe
Apil
ASACOL HD
mesalamine
TABLET, DELAYED RELEASE;ORAL021830-001May 29, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ASACOL HD

Drugname Dosage Strength RLD Submissiondate
mesalamineDelayed-release Tablets800 mgAsacol HD7/13/2011

International Patent Family for Tradename: ASACOL HD

Country Document Number Estimated Expiration
Denmark1453487► Subscribe
Australia2002226955► Subscribe
MexicoPA04004747► Subscribe
Spain2301575► Subscribe
Japan4999037► Subscribe
World Intellectual Property Organization (WIPO)03045356► Subscribe
European Patent Office1453487► Subscribe
Japan2005510539► Subscribe
China1314390► Subscribe
Austria389389► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
UBS
Queensland Health
Teva
US Army
McKesson
QuintilesIMS
Healthtrust
Argus Health
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot